Login
$PALI
$1.03 +$0.00 (0.0%) After hours

$PALI SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 8-K: Results of Operations and Financial Condition

First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027

10 Nov 2026 10-Q
09 Nov 2026 SCHEDULE 13G/A
30 Oct 2026 SCHEDULE 13G
21 Oct 2026 Form 4: Capers Julien E., See Remarks

Received 787,300 shares as a grant or award

21 Oct 2026 Form 3: Capers Julien E., See Remarks

No securities owned

07 Oct 2026 Form 4: Jones Mitchell Lawrence, See Remarks

Received 2,620,850 shares by exercise or conversion · Gave up 1,031,102 shares to cover exercise price or tax ($1.54M)

07 Oct 2026 Form 4: Finley John David, Director

Received 3,227,384 shares by exercise or conversion · Gave up 1,411,982 shares to cover exercise price or tax ($2.1M)

05 Oct 2026 Form 4: Williams Donald Allen, Director

Bought 10,000 shares ($14.2K) · Bought 10,000 shares ($14.6K)

21 Aug 2026 Form 4: Finley John David, Director

Gave 88,400 shares as a gift · Acquired 88,400 shares (Gift)

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G/A
10 Aug 2026 10-Q
10 Aug 2026 8-K: Results of Operations and Financial Condition

Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development

29 Jul 2026 SCHEDULE 13G
10 Jul 2026 Form 4: Baltera Robert Jr., Director

Bought 20,000 shares ($39.8K) · Bought 25,000 shares ($48.9K)

08 Jul 2026 Form 4: Baltera Robert Jr., Director

Bought 20,000 shares ($41K) · Bought 30,000 shares ($61K)

08 Jul 2026 Form 4: Jones Mitchell Lawrence, Chief Medical Officer

Received 131,167 shares by exercise or conversion · Sold 51,880 shares ($107K)

08 Jul 2026 Form 4: Finley John David, Director

Received 335,167 shares by exercise or conversion · Sold 146,798 shares ($303K) · Received 133 shares by exercise or conversion ($93.1)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support